| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/26/2023 | 20.18% | Citigroup | $625 → $530 | Maintains | Buy |
| 10/26/2023 | 16.78% | Raymond James | $580 → $515 | Maintains | Outperform |
| 10/26/2023 | 23.58% | Morgan Stanley | $600 → $545 | Maintains | Overweight |
| 10/26/2023 | — | Keybanc | Downgrades | Overweight → Sector Weight | |
| 10/24/2023 | 36.05% | Morgan Stanley | $640 → $600 | Maintains | Overweight |
| 10/18/2023 | 31.52% | Raymond James | $630 → $580 | Maintains | Outperform |
| 10/17/2023 | 42.86% | JP Morgan | $670 → $630 | Maintains | Overweight |
| 10/02/2023 | 41.72% | Citigroup | $625 → $625 | Reiterates | Buy → Buy |
| 09/28/2023 | 36.73% | Bernstein | → $603 | Initiates Coverage On | → Outperform |
| 09/06/2023 | 41.72% | Citigroup | → $625 | Reinstates | Buy → Buy |
| 07/28/2023 | 17.91% | Wells Fargo | $505 → $520 | Maintains | Underweight |
| 07/28/2023 | 42.86% | Raymond James | $595 → $630 | Maintains | Outperform |
| 07/27/2023 | 45.12% | Morgan Stanley | $620 → $640 | Maintains | Overweight |
| 07/27/2023 | 58.28% | RBC Capital | $662 → $698 | Maintains | Outperform |
| 07/27/2023 | 51.93% | JP Morgan | $660 → $670 | Maintains | Overweight |
| 07/27/2023 | 41.72% | Baird | $664 → $625 | Maintains | Outperform |
| 07/27/2023 | 41.72% | Barclays | $590 → $625 | Maintains | Overweight |
| 07/13/2023 | 40.59% | Credit Suisse | → $620 | Upgrades | Neutral → Outperform |
| 05/25/2023 | 49.66% | JP Morgan | $675 → $660 | Maintains | Overweight |
| 05/25/2023 | 45.12% | Keybanc | $710 → $640 | Maintains | Overweight |
| 04/27/2023 | 47.39% | Citigroup | $700 → $650 | Maintains | Buy |
| 04/27/2023 | 50.11% | RBC Capital | $664 → $662 | Maintains | Outperform |
| 04/27/2023 | 40.59% | Morgan Stanley | $670 → $620 | Maintains | Overweight |
| 04/27/2023 | 57.14% | TD Cowen | $711 → $693 | Maintains | Outperform |
| 04/27/2023 | 51.93% | Baird | $693 → $670 | Maintains | Outperform |
| 04/27/2023 | 38.32% | Barclays | $625 → $610 | Maintains | Overweight |
| 04/04/2023 | 38.32% | Evercore ISI Group | $615 → $610 | Maintains | Outperform |
| 04/04/2023 | 41.72% | Barclays | $660 → $625 | Maintains | Overweight |
| 02/02/2023 | 53.06% | JP Morgan | $650 → $675 | Maintains | Overweight |
| 02/02/2023 | 61.22% | Cowen & Co. | $690 → $711 | Maintains | Outperform |
| 02/02/2023 | 58.73% | Citigroup | $650 → $700 | Maintains | Buy |
| 02/02/2023 | 51.93% | Morgan Stanley | $613 → $670 | Maintains | Overweight |
| 02/02/2023 | 49.66% | Barclays | $630 → $660 | Maintains | Overweight |
| 02/02/2023 | 42.86% | SVB Leerink | $620 → $630 | Maintains | Outperform |
| 01/24/2023 | 42.86% | Barclays | $570 → $630 | Maintains | Overweight |
| 01/06/2023 | 40.59% | SVB Leerink | $555 → $620 | Maintains | Outperform |
| 01/03/2023 | 14.51% | Wells Fargo | $525 → $505 | Maintains | Underweight |
| 12/14/2022 | 40.59% | Deutsche Bank | → $620 | Initiates Coverage On | → Buy |
| 12/07/2022 | 49.89% | RBC Capital | → $661 | Initiates Coverage On | → Outperform |
| 11/29/2022 | 29.25% | Barclays | $575 → $570 | Maintains | Overweight |
| 11/01/2022 | 50.79% | Baird | $695 → $665 | Maintains | Outperform |
| 10/27/2022 | 47.39% | JP Morgan | $715 → $650 | Maintains | Overweight |
| 10/27/2022 | 47.39% | Citigroup | $715 → $650 | Maintains | Buy |
| 10/27/2022 | 30.39% | Barclays | $595 → $575 | Maintains | Overweight |
| 10/27/2022 | 39% | Morgan Stanley | $678 → $613 | Maintains | Overweight |
| 10/27/2022 | 25.85% | SVB Leerink | $590 → $555 | Maintains | Outperform |
| 09/12/2022 | 34.92% | Barclays | $685 → $595 | Maintains | Overweight |
| 08/25/2022 | 53.06% | Credit Suisse | → $675 | Initiates Coverage On | → Neutral |
| 08/01/2022 | 55.33% | Barclays | $630 → $685 | Maintains | Overweight |
| 07/29/2022 | 62.13% | JP Morgan | $700 → $715 | Maintains | Overweight |
| 07/29/2022 | 53.74% | Morgan Stanley | $670 → $678 | Maintains | Overweight |
| 07/29/2022 | 47.39% | SVB Leerink | $630 → $650 | Maintains | Outperform |
| 07/13/2022 | 42.86% | Barclays | $675 → $630 | Maintains | Overweight |
| 04/29/2022 | 51.93% | Morgan Stanley | $700 → $670 | Maintains | Overweight |
| 04/25/2022 | 19.05% | Wells Fargo | $605 → $525 | Downgrades | Equal-Weight → Underweight |
| 02/03/2022 | 37.19% | Wells Fargo | $700 → $605 | Maintains | Equal-Weight |
| 12/14/2021 | 58.73% | Wells Fargo | $625 → $700 | Maintains | Equal-Weight |
| 10/28/2021 | 62.13% | Citigroup | $700 → $715 | Maintains | Buy |
| 10/28/2021 | 55.33% | SVB Leerink | $675 → $685 | Maintains | Outperform |
| 10/20/2021 | 58.73% | Citigroup | $620 → $700 | Upgrades | Neutral → Buy |
| 09/23/2021 | 48.53% | Cowen & Co. | $560 → $655 | Maintains | Outperform |
| 09/22/2021 | 58.73% | BTIG | $610 → $700 | Maintains | Buy |
| 09/20/2021 | 58.73% | JP Morgan | $600 → $700 | Maintains | Overweight |
| 09/20/2021 | 61% | Keybanc | $555 → $710 | Maintains | Overweight |
| 08/04/2021 | 36.05% | Argus Research | $530 → $600 | Maintains | Buy |
| 07/29/2021 | 36.05% | JP Morgan | $560 → $600 | Maintains | Overweight |
| 07/16/2021 | 31.52% | Benchmark | → $580 | Initiates Coverage On | → Buy |
| 07/12/2021 | 25.85% | Keybanc | $520 → $555 | Maintains | Overweight |
| 06/23/2021 | 24.72% | Baird | $545 → $550 | Maintains | Outperform |
| 06/15/2021 | 20.18% | Goldman Sachs | $590 → $530 | Maintains | Buy |
| 04/16/2021 | 22.45% | Evercore ISI Group | $525 → $540 | Maintains | Outperform |
| 03/29/2021 | 26.98% | UBS | $588 → $560 | Maintains | Buy |
| 03/18/2021 | 17.91% | Keybanc | → $520 | Upgrades | Sector Weight → Overweight |
| 03/03/2021 | 19.05% | Barclays | → $525 | Initiates Coverage On | → Overweight |
| 02/03/2021 | 33.79% | BTIG | $540 → $590 | Maintains | Buy |
| 02/02/2021 | 20.18% | Citigroup | $500 → $530 | Maintains | Buy |
| 02/02/2021 | 33.33% | UBS | $566 → $588 | Maintains | Buy |
| 02/02/2021 | 32.65% | Cowen & Co. | $525 → $585 | Maintains | Outperform |
| 02/02/2021 | 36.05% | Stifel | $530 → $600 | Maintains | Buy |
| 02/02/2021 | 30.39% | Morgan Stanley | $535 → $575 | Maintains | Overweight |
| 02/02/2021 | 26.98% | SVB Leerink | $525 → $560 | Maintains | Outperform |
| 01/12/2021 | 31.52% | Credit Suisse | $556 → $580 | Maintains | Outperform |
| 01/08/2021 | 26.08% | Credit Suisse | $490 → $556 | Upgrades | Neutral → Outperform |
| 12/16/2020 | — | Citigroup | Downgrades | Buy → Neutral | |
| 12/02/2020 | 11.11% | Credit Suisse | $488 → $490 | Maintains | Neutral |
| 11/10/2020 | — | Keybanc | Initiates Coverage On | → Sector Weight | |
| 10/22/2020 | 10.66% | Credit Suisse | $432 → $488 | Maintains | Neutral |
| 10/22/2020 | 21.32% | Morgan Stanley | $485 → $535 | Maintains | Overweight |
| 10/22/2020 | 19.05% | SVB Leerink | $470 → $525 | Maintains | Outperform |
| 09/30/2020 | — | Atlantic Equities | Initiates Coverage On | → Overweight | |
| 09/17/2020 | 8.16% | Needham | $468 → $477 | Maintains | Buy |
| 09/14/2020 | 9.98% | Morgan Stanley | → $485 | Initiates Coverage On | → Overweight |
| 09/11/2020 | 8.84% | B of A Securities | $460 → $480 | Maintains | Buy |
| 09/11/2020 | -2.04% | Credit Suisse | $425 → $432 | Maintains | Neutral |
| 09/11/2020 | 6.58% | SVB Leerink | $455 → $470 | Maintains | Outperform |
| 08/21/2020 | -3.63% | Credit Suisse | $405 → $425 | Maintains | Neutral |
| 08/20/2020 | 4.31% | JP Morgan | → $460 | Reinstates | → Overweight |
| 07/23/2020 | 6.12% | Needham | $415 → $468 | Maintains | Buy |
| 07/23/2020 | 3.17% | SVB Leerink | $365 → $455 | Maintains | Outperform |
| 07/15/2020 | — | Cleveland Research | Upgrades | Neutral → Buy | |
| 07/07/2020 | -5.9% | Needham | $383 → $415 | Maintains | Buy |
| 04/23/2020 | -11.56% | Citigroup | $365 → $390 | Maintains | Buy |
| 04/23/2020 | -13.15% | Needham | $341 → $383 | Maintains | Buy |
| 04/21/2020 | -22.9% | Wells Fargo | $300 → $340 | Maintains | Equal-Weight |
| 04/02/2020 | -28.57% | Stifel | $345 → $315 | Maintains | Buy |
| 03/30/2020 | -31.97% | Wells Fargo | $345 → $300 | Maintains | Equal-Weight |
| 03/20/2020 | -17.23% | Citigroup | $390 → $365 | Maintains | Buy |
| 03/04/2020 | -22.68% | Baird | $340 → $341 | Maintains | Outperform |
| 01/31/2020 | -15.65% | BTIG | $342 → $372 | Maintains | Buy |
| 01/31/2020 | -22.9% | Baird | $319 → $340 | Maintains | Outperform |
| 01/31/2020 | -21.77% | Wells Fargo | $350 → $345 | Maintains | Equal-Weight |
| 01/31/2020 | -11.56% | Citigroup | $380 → $390 | Maintains | Buy |
| 01/22/2020 | -22.68% | Credit Suisse | → $341 | Initiates Coverage On | → Neutral |
| 01/08/2020 | -20.63% | Wells Fargo | → $350 | Initiates Coverage On | → Equal-Weight |
| 01/07/2020 | -13.83% | Citigroup | → $380 | Initiates Coverage On | → Buy |
| 11/15/2019 | -21.77% | Stifel | → $345 | Initiates Coverage On | → Buy |
| 10/24/2019 | -27.66% | Baird | $305 → $319 | Maintains | Outperform |
| 07/25/2019 | -27.21% | Needham | $315 → $321 | Maintains | Buy |
| 07/16/2019 | -28.57% | Needham | → $315 | Downgrades | Strong Buy → Buy |
| 05/23/2019 | -27.44% | UBS | $305 → $320 | Maintains | Buy |
| 05/01/2019 | -29.71% | Argus Research | $285 → $310 | Maintains | Buy |
| 03/26/2019 | -34.69% | Baird | $270 → $288 | Maintains | Outperform |
| 03/22/2019 | -31.97% | Deutsche Bank | $275 → $300 | Maintains | Buy |
| 03/18/2019 | -31.97% | Barclays | $295 → $300 | Maintains | Overweight |
| 01/03/2019 | -36.51% | Barclays | $275 → $280 | Maintains | Overweight |
| 01/03/2019 | -38.55% | Needham | → $271 | Initiates Coverage On | → Strong Buy |
What is the target price for Thermo Fisher Scientific (TMO)?
The latest price target for Thermo Fisher Scientific (NYSE: TMO) was reported by Citigroup on October 26, 2023. The analyst firm set a price target for $530.00 expecting TMO to rise to within 12 months (a possible 20.18% upside). 46 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Thermo Fisher Scientific (TMO)?
The latest analyst rating for Thermo Fisher Scientific (NYSE: TMO) was provided by Citigroup, and Thermo Fisher Scientific maintained their buy rating.
When is the next analyst rating going to be posted or updated for Thermo Fisher Scientific (TMO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Thermo Fisher Scientific, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Thermo Fisher Scientific was filed on October 26, 2023 so you should expect the next rating to be made available sometime around October 26, 2024.
Is the Analyst Rating Thermo Fisher Scientific (TMO) correct?
While ratings are subjective and will change, the latest Thermo Fisher Scientific (TMO) rating was a maintained with a price target of $625.00 to $530.00. The current price Thermo Fisher Scientific (TMO) is trading at is $441.00, which is out of the analyst's predicted range.